Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
Poor sleep in patients with multiple sclerosis.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Laquinimod for multiple sclerosis.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Centocor briefing document for Ustekinumab, submitted to FDA
T cells become licensed in the lung to enter the central nervous system.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Stress and the risk of multiple sclerosis.
Shorter washout reduces MS relapse switching off natalizumab
[Infections and fingolimod].

Pages